{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IIV",
    "query": {
      "intervention": "IIV"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 47,
    "total_pages": 5,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IIV&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-03T09:12:21.063Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03589807",
      "title": "2013/2017 H7N9 Prime-Boost Interval",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Avian Influenza",
        "Influenza Immunisation"
      ],
      "interventions": [
        {
          "name": "A/H7N9",
          "type": "BIOLOGICAL"
        },
        {
          "name": "AS03",
          "type": "DRUG"
        },
        {
          "name": "Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Phosphate Buffered Saline (PBS) diluent",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "19 Years to 50 Years"
      },
      "enrollment_count": 180,
      "start_date": "2018-08-21",
      "completion_date": "2020-06-14",
      "has_results": true,
      "last_update_posted_date": "2021-08-02",
      "last_synced_at": "2026-09-03T09:12:21.063Z",
      "location_count": 6,
      "location_summary": "Atlanta, Georgia • Decatur, Georgia • Iowa City, Iowa + 3 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Decatur",
          "state": "Georgia"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03589807"
    },
    {
      "nct_id": "NCT05501561",
      "title": "Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults ≥50 Years of Age",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Influenza, Human"
      ],
      "interventions": [
        {
          "name": "Experimental: IIV-A Investigational IIV-A administered as a single dose intramuscularly on Day 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Experimental: aIIV-B Investigational aIIV-B administered as a single dose intramuscularly on Day 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Experimental: aIIV-C Investigational aIIV-C administered as a single dose intramuscularly on Day 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Active Comparator: Licensed IIV IIV administered as a single dose intramuscularly on Day 1",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Seqirus",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 1056,
      "start_date": "2022-08-25",
      "completion_date": "2023-03-31",
      "has_results": true,
      "last_update_posted_date": "2026-06-30",
      "last_synced_at": "2026-09-03T09:12:21.063Z",
      "location_count": 47,
      "location_summary": "Tempe, Arizona • Huntington Beach, California • San Diego, California + 42 more",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Milford",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05501561"
    },
    {
      "nct_id": "NCT05397119",
      "title": "A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Pandemic Flu Vaccine in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Influenza, Pandemic"
      ],
      "interventions": [
        {
          "name": "BW-1014: 25 µg rH5 in 20% NE - pipette - IN",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BW-1014: 50 µg rH5 in 20% NE - pipette - IN",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BW-1014: 100 µg rH5 in 20% NE - pipette - IN",
          "type": "BIOLOGICAL"
        },
        {
          "name": "rH5 (100 µg) control - pipette - IN",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Saline (Placebo) - pipette - IN",
          "type": "BIOLOGICAL"
        },
        {
          "name": "H5N1 IIV - IM",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "BlueWillow Biologics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 40,
      "start_date": "2022-07-07",
      "completion_date": "2023-10-12",
      "has_results": true,
      "last_update_posted_date": "2026-07-30",
      "last_synced_at": "2026-09-03T09:12:21.063Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05397119"
    },
    {
      "nct_id": "NCT02967393",
      "title": "Influenza Vaccine Feasibility Study in Children With Persistent Asthma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Asthmatic"
      ],
      "interventions": [
        {
          "name": "ccIIV4",
          "type": "DRUG"
        },
        {
          "name": "IIV4",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vanderbilt University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "11 Years",
        "sex": "ALL",
        "summary": "5 Years to 11 Years"
      },
      "enrollment_count": 40,
      "start_date": "2016-10-10",
      "completion_date": "2017-02-01",
      "has_results": true,
      "last_update_posted_date": "2018-04-23",
      "last_synced_at": "2026-09-03T09:12:21.063Z",
      "location_count": 4,
      "location_summary": "Atlanta, Georgia • Durham, North Carolina • Cincinnati, Ohio + 1 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02967393"
    },
    {
      "nct_id": "NCT03300050",
      "title": "Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Influenza",
        "Vaccine"
      ],
      "interventions": [
        {
          "name": "cH8/1N1 LAIV",
          "type": "BIOLOGICAL"
        },
        {
          "name": "AS03-adjuvanted cH5/1N1 IIV",
          "type": "BIOLOGICAL"
        },
        {
          "name": "cH5/1N1 IIV",
          "type": "BIOLOGICAL"
        },
        {
          "name": "AS03-adjuvanted cH8/1N1 IIV",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Normal saline",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Phosphate buffered saline (PBS)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "PATH",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "39 Years",
        "sex": "ALL",
        "summary": "18 Years to 39 Years"
      },
      "enrollment_count": 65,
      "start_date": "2017-10-10",
      "completion_date": "2019-08-09",
      "has_results": true,
      "last_update_posted_date": "2021-02-21",
      "last_synced_at": "2026-09-03T09:12:21.063Z",
      "location_count": 2,
      "location_summary": "Durham, North Carolina • Cincinnati, Ohio",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03300050"
    },
    {
      "nct_id": "NCT06029933",
      "title": "Fluad vs. Fluzone High-Dose Vaccine Effectiveness Among Adults ≥65 Years",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Influenza",
        "Community-acquired Pneumonia",
        "Cardiovascular Events"
      ],
      "interventions": [
        {
          "name": "Adjuvanted Quadrivalent Inactivated Influenza Vaccine (aIIV4)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "High-Dose Quadrivalent Inactivated Influenza Vaccine (HD-IIV4)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Kaiser Permanente",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 1500000,
      "start_date": "2023-08-17",
      "completion_date": "2028-05",
      "has_results": false,
      "last_update_posted_date": "2026-08-05",
      "last_synced_at": "2026-09-03T09:12:21.063Z",
      "location_count": 1,
      "location_summary": "Oakland, California",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06029933"
    },
    {
      "nct_id": "NCT03472976",
      "title": "H5N1 With or Without Topical Aldara in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Avian Influenza",
        "Influenza Immunisation"
      ],
      "interventions": [
        {
          "name": "Aqueous Cream B.P.",
          "type": "OTHER"
        },
        {
          "name": "Imiquimod",
          "type": "DRUG"
        },
        {
          "name": "Influenza Virus Vaccine, Monovalent A/H5N1 A/Vietnam/1203/04",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 50,
      "start_date": "2018-06-13",
      "completion_date": "2019-03-04",
      "has_results": false,
      "last_update_posted_date": "2020-02-24",
      "last_synced_at": "2026-09-03T09:12:21.063Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03472976"
    },
    {
      "nct_id": "NCT01764269",
      "title": "Assessing Fever Rates in Children Ages 24 to 59 Months After Live Attenuated Influenza Vaccine (LAIV) or Inactivated Influenza Vaccines (IIV) Using Text Messaging for U.S. Influenza Vaccines in 2012-2013 & 2013-2014",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Fever"
      ],
      "interventions": [
        {
          "name": "text message surveillance for fever",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "24 Months",
        "maximum_age": "59 Months",
        "sex": "ALL",
        "summary": "24 Months to 59 Months"
      },
      "enrollment_count": 656,
      "start_date": "2013-01",
      "completion_date": "2014-05",
      "has_results": false,
      "last_update_posted_date": "2014-06-24",
      "last_synced_at": "2026-09-03T09:12:21.063Z",
      "location_count": 2,
      "location_summary": "Atlanta, Georgia • New York, New York",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01764269"
    },
    {
      "nct_id": "NCT01946594",
      "title": "Clinical Immunization Safety Assessment (CISA) Project: Pilot Study to Assess the Effect of Prophylactic Antipyretics on Immune Responses and Fever After IIV",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Fever"
      ],
      "interventions": [
        {
          "name": "Acetaminophen",
          "type": "OTHER"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "35 Months",
        "sex": "ALL",
        "summary": "12 Months to 35 Months"
      },
      "enrollment_count": 41,
      "start_date": "2013-10",
      "completion_date": "2014-03",
      "has_results": false,
      "last_update_posted_date": "2016-01-20",
      "last_synced_at": "2026-09-03T09:12:21.063Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01946594"
    },
    {
      "nct_id": "NCT04785794",
      "title": "Safety and Immunogenicity of the Sing2016 M2SR H3N2 Monovalent Influenza Vaccine in Adults Ages 50 to 85 Years Old",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Influenza Vaccine"
      ],
      "interventions": [
        {
          "name": "Sing2016 M2SR H3N2 influenza vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "FluGen Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "50 Years to 85 Years"
      },
      "enrollment_count": 122,
      "start_date": "2021-06-30",
      "completion_date": "2021-11-30",
      "has_results": true,
      "last_update_posted_date": "2023-06-15",
      "last_synced_at": "2026-09-03T09:12:21.063Z",
      "location_count": 3,
      "location_summary": "Anaheim, California • DeLand, Florida • Lenexa, Kansas",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "DeLand",
          "state": "Florida"
        },
        {
          "city": "Lenexa",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04785794"
    }
  ]
}